Member Info for RayPointer

IMO it's definitely not partner time.
Get the data and then partner has always been the Scancell mantra.
Looks like we will have to wait 4 days after first patient dosed to get the data :-)

But what stands out for me is "up to 20 trial centres". Surely this tells us that Modi1 creating quite a stir already in clinical circles.

I recollect that Sally said that the enolase peptide had been manufactured and the one remaining task was to combine the 3 peptides. I might be wrong, but isn't the complete manufacture a precondition of the trial being approved.
I stand to be corrected.

Good stuff Bermuda
From the "about us" page

https://www.mewburn.com/about-us

"As one of Europe’s top specialist Intellectual Property firms we believe in a personal approach to business. Our focus is on providing strategic advice to maximise the potential of your IP as an asset and so increase the value of your business. We can be counted on to be one step ahead, looking at how you can best exploit your IP portfolio both now and in the future. We’re known for providing clear, concise and to the point IP advice. We won’t crush new ideas at early stages, but from the outset we’ll be clear on what will and won’t work from an IP perspective."

Now I speculate that either this company is already advising Scancell or it very much wants to.
Other views may be avaialble :-)

Thanks Johnny.
Perhaps Lindy is keeping CEPI informed of emerging data. I will leave team doom and gloom to provide balance.

Looks like a happy clappy day today after yesterday's doom and gloom

Good point Burble.
This is especially true if Lindy and Co can isolate the effect that avidimab is having on the Covidity efficacy
I hope you are beginning to feel better

AB
There is, of course, always risk of clinical stage failure. Most trials do fail
But what moon is saying that we are steadily reducing the risk by getting the products to the clinical stage and into the clinic.

Yes, it is slow progress on the trials themselves but the risk is steadily being eroded.
We can discuss until the cows come home about the residual risk.

Look at it another way:

The SP peaked at 28p in Feb 21.
Since then:
a) The Covidity trial has started and 22 patients have been dosed with no safety issues and good initial data
b) A patient has been dosed for the SCIB1 combo trial
c) Modi1 trial has been approved
d) We have been told that Lindy turned down 2 glycans deals
e) A 4th glycans collaboration has been announced and 4 of the mAbs have now been humanised (that's probably a big hurdle in the progress towards the clinic)

and now the SP is 11p.
What does that say about the Aim market? It swings from over bought to over sold, perhaps in contradiction to what is actually being achieved by the company.

I believe moon is right.

You can also add that:

Covidity is proving to be safe and initial immunigenicity data is promising

For Glymab, 2 deals have been turned down and a fourth research partner has been added and as more research is done
the partnerships remain intact. We also know that 4 or the 5 mAbs have been humanised. We don't know how far this is from clinical trials but it's got to be getting closer
But let's not get bogged down

Yes, it is slow.
But the big positive from the RNS is the entry criteria have been widened dramatically. Hopefully the 18 remaining people will be quickly recruited.

Thanks for that Seis.
Interesting. I don't know whether the timing of the WHI note is before or after Leon's statement that we would have to await Elephant before Cobalt appears in any appreciable volumes.
If we see some Cobalt production this year it would be a great bonus IMO

I don't think Cobalt features in any decent volumes until Elephant starts producing.

Get well soon Burble

I see there are Blackburn fans on this BB

I'm suffering from memory loss about where I put my shares.

Interesting to see that Clive Mulatero helped produce this article on SCIB1 back in 2018.

https://pubmed.ncbi.nlm.nih.gov/29872563/

Clive has since gone up in the world

https://www.linkedin.com/in/clive-mulatero-72b69938

He is now Associate Vice President, Global Head of Oncology Scientific Affairs at Merck.
Not that I am implying anything here :-)

Lindy's reply

Can you call back later, I am busy at present curing all cancers
:-)

To carry on from crumbs last post

The potential of Scancell's products will potentially lead to deals of potentially large amounts.

AB
Why the obsession with how many shares that C7 holds?

in this same RNS

"The Scancell team and collaborators remain convinced that a more durable and broader-acting vaccine is required to combat the global pandemic and we are encouraged by the emerging data supporting the use of our vaccines against new variants."

I think Lindy will follow plan A which is to complete the trial and then publish the data. If the data lives up to expectations, then there may be more than one company and/or CEPI looking to do a deal.

Scancell obviously need a counter on their website indicating patients doesd :-)

my SP predictions are always 100% correct